Preclinical development of gene therapy for Parkinson's disease.
Identifieur interne : 002487 ( Main/Merge ); précédent : 002486; suivant : 002488Preclinical development of gene therapy for Parkinson's disease.
Auteurs : Grégory Porras [France] ; Erwan BezardSource :
- Experimental neurology [ 0014-4886 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Neuroprotective Agents.
- therapy : Parkinson Disease.
- trends : Genetic Therapy.
- Animals, Clinical Trials as Topic, Humans.
Abstract
Multiple targets and pathways may be amenable to the development of gene therapy approaches for Parkinson's disease. This article discusses some of the cellular and brain circuit pathways relevant to Parkinson's disease that would be clinically amenable to gene therapy. Approaches could be classified according to two main categories, i.e. symptomatic vs. neuroprotective/neurorestorative strategies. Examples of the different possibilities currently in development are given and feature both dopaminergic and non-dopaminergic symptomatic treatments of parkinsonian symptoms and/or L-DOPA-induced side effects, anti-apoptotic neuroprotective strategies and growth-factor delivery for neuroprotection/neurorestoration. While gene therapy has been mostly used so far for enhancing the expression of the target gene, the use of dominant negative or siRNA opens new possibilities. This, combined with the key feature of gene delivery that offers access to intracellular signalling pathways, is likely to further expand the number of proposed targets to be studied.
DOI: 10.1016/j.expneurol.2007.08.003
PubMed: 17904121
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D26
- to stream PubMed, to step Curation: 000C86
- to stream PubMed, to step Checkpoint: 000C86
- to stream Ncbi, to step Merge: 000773
- to stream Ncbi, to step Curation: 000773
- to stream Ncbi, to step Checkpoint: 000773
Links to Exploration step
pubmed:17904121Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preclinical development of gene therapy for Parkinson's disease.</title><author><name sortKey="Porras, Gregory" sort="Porras, Gregory" uniqKey="Porras G" first="Grégory" last="Porras">Grégory Porras</name><affiliation wicri:level="3"><nlm:affiliation>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2, 33076, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2, 33076, Bordeaux</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:17904121</idno><idno type="pmid">17904121</idno><idno type="doi">10.1016/j.expneurol.2007.08.003</idno><idno type="wicri:Area/PubMed/Corpus">000D26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D26</idno><idno type="wicri:Area/PubMed/Curation">000C86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C86</idno><idno type="wicri:Area/PubMed/Checkpoint">000C86</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C86</idno><idno type="wicri:Area/Ncbi/Merge">000773</idno><idno type="wicri:Area/Ncbi/Curation">000773</idno><idno type="wicri:Area/Ncbi/Checkpoint">000773</idno><idno type="wicri:doubleKey">0014-4886:2008:Porras G:preclinical:development:of</idno><idno type="wicri:Area/Main/Merge">002487</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Preclinical development of gene therapy for Parkinson's disease.</title><author><name sortKey="Porras, Gregory" sort="Porras, Gregory" uniqKey="Porras G" first="Grégory" last="Porras">Grégory Porras</name><affiliation wicri:level="3"><nlm:affiliation>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2, 33076, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2, 33076, Bordeaux</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author></analytic><series><title level="j">Experimental neurology</title><idno type="ISSN">0014-4886</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Dopamine Agents (therapeutic use)</term><term>Genetic Therapy (trends)</term><term>Humans</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Genetic Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple targets and pathways may be amenable to the development of gene therapy approaches for Parkinson's disease. This article discusses some of the cellular and brain circuit pathways relevant to Parkinson's disease that would be clinically amenable to gene therapy. Approaches could be classified according to two main categories, i.e. symptomatic vs. neuroprotective/neurorestorative strategies. Examples of the different possibilities currently in development are given and feature both dopaminergic and non-dopaminergic symptomatic treatments of parkinsonian symptoms and/or L-DOPA-induced side effects, anti-apoptotic neuroprotective strategies and growth-factor delivery for neuroprotection/neurorestoration. While gene therapy has been mostly used so far for enhancing the expression of the target gene, the use of dominant negative or siRNA opens new possibilities. This, combined with the key feature of gene delivery that offers access to intracellular signalling pathways, is likely to further expand the number of proposed targets to be studied.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002487 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002487 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:17904121
|texte= Preclinical development of gene therapy for Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:17904121" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |